Perspective on in vivo SPME for human applications: Starting from monitoring doxorubicin during lung chemo-perfusion
Journal of Pharmaceutical Analysis · 2024-07 · 14 (7) · 100918
DOI: 10.1016/j.jpha.2023.12.008 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Pharmaceutical Analysis, 2024-07. Verfasst von Wei Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Waterloo, Waterloo, ON N2L 3G1, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, National Institute of Mental Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Chemistry, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
- Department of Pharmacodynamics and Molecular Pharmacology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089, Bydgoszcz, Poland.
Förderung
- Natural Sciences and Engineering Research Council of Canada
- National Institute of Mental Health
Zitieren
APA
Zhou, W., Jiang, R. W., Bojko, B., & Pawliszyn, J. (2024). Perspective on in vivo SPME for human applications: Starting from monitoring doxorubicin during lung chemo-perfusion. Journal of Pharmaceutical Analysis, 14(7), 100918. https://doi.org/10.1016/j.jpha.2023.12.008
Vancouver
Zhou W, Jiang RW, Bojko B, Pawliszyn J. Perspective on in vivo SPME for human applications: Starting from monitoring doxorubicin during lung chemo-perfusion. Journal of Pharmaceutical Analysis. 2024;14(7):100918. doi:10.1016/j.jpha.2023.12.008
BibTeX
@article{Zhou2024,
author = {Zhou, Wei and Jiang, Runshan Will and Bojko, Barbara and Pawliszyn, Janusz},
title = {Perspective on in vivo SPME for human applications: Starting from monitoring doxorubicin during lung chemo-perfusion},
journal = {Journal of Pharmaceutical Analysis},
year = {2024},
volume = {14},
number = {7},
pages = {100918},
doi = {10.1016/j.jpha.2023.12.008}
}
EUVIMED